131 results
8-K/A
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
7:18pm
certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may … defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify … litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
12 Mar 24
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
8:30am
that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify … and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation
8-K
EX-99.1
eqt7kw0k n9vme
13 Nov 23
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9:00am
8-K
p5u2erzczkjstw
30 Aug 23
Other Events
8:41pm
8-K
EX-99.1
zkjexs6ymqsryqf8ko
14 Aug 23
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8:30am
8-K
EX-1.1
xjbu8
23 Mar 21
Entry into a Material Definitive Agreement
6:01am